Three weeks after Belgian pharma UCB finalized its $1.9 billion acquisition of California-based biotech Zogenix, its newly-acquired epilepsy drug fenfluramine got the seal of approval from the FDA for a new indication: Lennox-Gastaut syndrome (LGS), a rare type of severe epilepsy, in patients ages two and up.
UCB made the announcement early Monday morning, exactly three weeks after UCB beat two other competitors in buying out Zogenix and its lead drug fenfluramine, also known as Fintepla, at $26 a share. At the time, UCB’s EVP of neurology and head of Europe/international markets Charl van Zyl said in a statement, “Utilizing our deep expertise, experience and global capabilities, we plan to accelerate access for patients to the treatment.”
Article From & Read More ( BREAKING: Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need? - Endpoints News )https://ift.tt/I58y9xC
Business
Bagikan Berita Ini
0 Response to "BREAKING: Amylyx shares routed on skeptical adcomm docs — but did the FDA leave an open door on unmet ALS need? - Endpoints News"
Post a Comment